Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
In this paper Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital and Chief Medical Officer at Devyser explains that, monitoring for mixed chimerism in patients after HSCT has in several studies been shown to be of 
clinical importance. The main purpose of the assay is 
to verify engraftment and subsequently monitor for 
the presence of MRD and potentially early detection 
of possible relapse.
In this paper Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital and Chief Medical Officer at Devyser explains that, monitoring for mixed chimerism in patients after HSCT has in several studies been shown to be of 
clinical importance. The main purpose of the assay is 
to verify engraftment and subsequently monitor for 
the presence of MRD and potentially early detection 
of possible relapse.
  Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
Read More
  Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
Read More
  Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of...
Read More
  Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant...
Read More